Interventional Cardiology

This cardiac subspecialty uses minimally invasive, catheter-based technologies in a cath lab to diagnose and treat coronary artery disease (CAD). The main focus in on percutaneous coronary interventions (PCI) to revascularize patients with CAD that is causing blockages resulting in ischemia or myocardial infarction. PCI mainly consists of angioplasty and implanting stents. Interventional cardiology has greatly expanded in scope over recent years to include a number of transcatheter structural heart interventions.

Self-donating blood for heart surgery cuts patients’ hospital stays, lowers transfusion rate

Patients undergoing heart surgery might see better outcomes and shorter hospital stays if they opt for intraoperative autologous blood donation, according to research out of New York.

Thumbnail

SCAI chimes in on concerns about paclitaxel devices

The Society for Cardiovascular Angiography and Interventions (SCAI) weighed in on the ongoing debate regarding the long-term safety of paclitaxel-coated balloons and stents on Jan. 25, largely agreeing with the FDA’s stance that the benefits of such devices appear to outweigh the risks until more information becomes available.

New data from the IMPERIAL clinical program demonstrates ELUVIA more effective in diabetic patients

LEIPZIG and MARLBOROUGH, Mass. (January 22, 2019) — Boston Scientific (NYSE: BSX) today announced diabetic subanalysis results from the IMPERIAL trial in which patients treated with the ELUVIA™ Drug-Eluting Vascular Stent System demonstrated statistically significant lower rates of target lesion revascularization (TLR) and stent thrombosis when compared to those treated with the Zilver® PTX® Drug-Eluting Peripheral Stent. 

Thumbnail

Culture of interventional cardiology drives women away

A survey of cardiovascular fellows-in-training (FIT) offered insight into why women at that career stage are less likely to pursue interventional cardiology—a subspecialty that ranks among the lowest in all of medicine in terms of female representation.

Rivaroxaban doesn’t improve graft patency after CABG

Rivaroxaban failed to reduce the rate of early graft failure following coronary artery bypass graft (CABG) surgery compared to aspirin monotherapy, researchers reported in a substudy of the COMPASS trial published Jan. 14 in the Journal of the American College of Cardiology.

Thumbnail

Long-term survival encouraging after surgical correction of PCI-related complications

One in five patients who required emergency surgery to correct complications caused by diagnostic angiography or percutaneous coronary intervention (PCI) died within 30 days, researchers reported in a single-center study from Germany.

Thumbnail

Unprotected left main PCI remains rare in US

Despite recent clinical trial evidence suggesting the outcomes of unprotected left main PCI rival those of coronary artery bypass grafting (CABG), very few unprotected left main PCIs are performed in everyday clinical practice in the United States.

Thumbnail

Are You Investing in Cath Lab Worker Health?

Sponsored by ORSIF

For-profit and not-for-profit healthcare facilities may value the health of their cath lab employees differently. Without a clear indication of the bottom-line impact, some hospitals may be forgoing protective equipment and sacrificing the long-term health of their workers. Should the C-suite prioritize worker health when allocating investment dollars?